Pharmacokinetic Modeling and [123I]5-IA-85380 Single Photon Emission Computed Tomography Imaging in Baboons: Optimization of Dosing Regimen for ABT-089

Neuronal acetylcholine nicotinic receptors (nAChRs) are targets for the development of novel treatments of brain diseases. However, adverse effects (for example, emesis or nausea) associated with high drug maximal exposures or Cmax at nAChRs often hinder the advancement of experimental compounds in clinical trials. Therefore, it is essential to explore the feasibility of maintaining exposures below a predetermined Cmax while sustaining targeted CNS effects. By use of a [123I]5-IA [5-[123I]iodo-3-[2(S)-azetidinylmethoxy]pyridine] displacement SPECT imaging paradigm in nonhuman primates, we compared brain nAChR binding activity elicited by either a bolus injection or by slow infusion of an identical dose of a novel neuronal nicotinic agonist, ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride], where the slow infusion scheme was derived from a two-compartment pharmacokinetic modeling designed to limit the Cmax. We determined [123I]5-IA displacement using doses of ABT-089 (0.04, 0.4, and 1.0 mg/kg i.v.) that encompassed efficacious drug exposures in nonhuman primates and examined the relationship between ABT-089 displacement ratios and plasma exposures. Our results indicated that calculated displacement ratios were quite similar between the two different dosing regimens despite substantial differences in Cmax. In addition, displacement ratios correlated well with drug exposures calculated as the area-under-curve (AUC) of plasma concentration and varied in a dose-dependent manner, suggesting that displacement ratios are driven by the AUC of drug plasma exposure but not Cmax. Our data demonstrate the feasibility of predicting plasma exposures using a two-compartment pharmacokinetic model and its potential for optimizing dosing regimens.

[1]  M. Day,et al.  Translational neuroimaging of the CNS: novel pathways to drug development. , 2009, Molecular interventions.

[2]  P. Hartig,et al.  Target site occupancy: emerging generalizations from clinical and preclinical studies. , 2009, Pharmacology & therapeutics.

[3]  L. Howell.  Nonhuman primate neuroimaging and cocaine medication development. , 2008, Experimental and clinical psychopharmacology.

[4]  Christoph Hiemke,et al.  Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. , 2008, The American journal of psychiatry.

[5]  R. Zipursky,et al.  PET and SPECT Imaging in Psychiatric Disorders , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[6]  R. Barthel.  The American Academy of Child and Adolescent Psychiatry , 2007, Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry.

[7]  D. Bertrand,et al.  Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. , 2007, Biochemical pharmacology.

[8]  M. Stolar,et al.  Multiple‐Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers , 2006, Journal of clinical pharmacology.

[9]  P. Fletcher,et al.  Dissociation between In Vivo Occupancy and Functional Antagonism of Dopamine D2 Receptors: Comparing Aripiprazole to Other Antipsychotics in Animal Models , 2006, Neuropsychopharmacology.

[10]  D. Donnelly-roberts,et al.  ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. , 2006, CNS drug reviews.

[11]  S. West,et al.  ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study , 2006, Biological Psychiatry.

[12]  J. Staley,et al.  Chemical fate of the nicotinic acetylcholinergic radiotracer [123I]5-IA-85380 in baboon brain and plasma. , 2006, Nuclear medicine and biology.

[13]  C. Gotti,et al.  Neuronal nicotinic receptors: from structure to pathology , 2004, Progress in Neurobiology.

[14]  Robert B. Innis,et al.  Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  R. Hargreaves,et al.  Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[16]  Gilles Tamagnan,et al.  Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5‐I‐A‐85380 , 2003, Synapse.

[17]  R. Lester,et al.  Desensitization of neuronal nicotinic receptors. , 2002, Journal of neurobiology.

[18]  Marc Laruelle,et al.  Neuroreceptor imaging in psychiatric disorders , 2002, Annals of nuclear medicine.

[19]  D. Sheehan,et al.  Nicotinic acetylcholine receptors as targets for antidepressants , 2002, Molecular Psychiatry.

[20]  J. Sullivan,et al.  The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control , 2001, Expert opinion on investigational drugs.

[21]  J. Seibyl,et al.  Measurement of α4β2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT , 2000 .

[22]  Agneta Nordberg,et al.  Neuronal nicotinic receptors in the human brain , 2000, Progress in Neurobiology.

[23]  Weiner,et al.  Methodology for pharmacokinetic/pharmacodynamic data analysis. , 1999, Pharmaceutical science & technology today.

[24]  D. Wong,et al.  Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. , 1999, Nuclear medicine and biology.

[25]  E. London,et al.  Radiosynthesis and preliminary evaluation of 5-[123/125I]iodo-3-(2(S)-azetidinylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors. , 1999, Nuclear medicine and biology.

[26]  J M Links,et al.  In vivo imaging of brain nicotinic acetylcholine receptors with 5-[123I]iodo-A-85380 using single photon emission computed tomography. , 1998, Life sciences.

[27]  E. London,et al.  2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. , 1998, Journal of medicinal chemistry.

[28]  W. J. Jackson,et al.  ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.

[29]  D. Donnelly-roberts,et al.  A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: In Vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand , 1996, Neuropharmacology.

[30]  C. Halldin,et al.  Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man , 1995, International clinical psychopharmacology.

[31]  Thomas M. Ludden,et al.  Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[32]  L. Farde,et al.  Influence of rate of administration of raclopride on akathisia and prolactin response , 1994, Psychopharmacology.

[33]  D. Beleslin,et al.  Further studies on nicotine-induced emesis: Nicotinic mediation in area postrema , 1987, Physiology & Behavior.

[34]  G. Gibson,et al.  Locomotor activity as a predictor of times and dosages for studies of nicotine's neurochemical actions , 1987, Pharmacology Biochemistry and Behavior.

[35]  M. Mattila,et al.  Pharmacokinetics of nicotine in adult and infant mice. , 1977, Medical biology.

[36]  Dean F Wong,et al.  The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development , 2009, Neuropsychopharmacology.

[37]  J. Seibyl,et al.  Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates. , 2001, Nuclear medicine and biology.

[38]  J. Seibyl,et al.  Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  W. J. Jackson,et al.  Central nicotinic receptor agonists ABT-418, ABT-089, and (–)-nicotine reduce distractibility in adult monkeys , 1998, Psychopharmacology.

[40]  D. Mckenna,et al.  A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand. , 1996, Neuropharmacology.

[41]  G. Sedvall,et al.  The potential of positron-emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics. , 1989, Psychopharmacology series.